Literature DB >> 4944633

Cell cycle-dependent immune lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to antibody, and complement activation.

R A Lerner, M B Oldstone, N R Cooper.   

Abstract

The expression of Moloney leukemia virus on the surface of a viral-induced lymphoma cell, availability of the virus to anti-viral antibody, and the nature and extent of activation of the complement system during the cell cycle were studied in vitro. Viral antigen was present on the cell surface, accessible to antibody, and was able to activate complement in the presence of antibody throughout all cellular growth phases, while cytotoxicity was confined to the G(1) phase of cell growth. In addition, when cells were arrested in metaphase, viral antigen could be demonstrated on the cell surface by immunofluorescence, and budding virus was seen by electron microscopy. All nine components of complement were activated on the addition of antibody throughout the cell cycle. Additional experiments indicated that in the presence of antibody, C3 and/or C4 were immunospecifically bound to viral-induced lymphoma cells throughout the cell cycle as a result of complement activation. These results indicate that the inability to lyse the cells in the presence of specific anti-viral antibody and complement during the logarithmic phase of cell growth is not due to the lack of expression of Moloney virus antigen(s) on the cell surface, inaccessibility of this surface antigen(s) to antibody, or failure to activate the complement effector system.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4944633      PMCID: PMC389473          DOI: 10.1073/pnas.68.10.2584

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  The integrated state of viral DNA in SV40-transformed cells.

Authors:  J Sambrook; H Westphal; P R Srinivasan; R Dulbecco
Journal:  Proc Natl Acad Sci U S A       Date:  1968-08       Impact factor: 11.205

2.  The ninth component of human complement: isolation, description and mode of action.

Authors:  U Hadding; H J Müller-Eberhard
Journal:  Immunology       Date:  1969-06       Impact factor: 7.397

Review 3.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1969       Impact factor: 23.643

4.  Direct immunofluorescent tissue culture assay for lymphocytic choriomeningitis virus.

Authors:  M B Oldstone; F J Dixon
Journal:  J Immunol       Date:  1968-05       Impact factor: 5.422

5.  Antigenic expression of a murine lymphoma during growth in vitro.

Authors:  M Cikes
Journal:  Nature       Date:  1970-02-14       Impact factor: 49.962

6.  The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis.

Authors:  N R Cooper; M J Polley; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1970-04

7.  Immune adherence by the fourth component of complement.

Authors:  N R Cooper
Journal:  Science       Date:  1969-07-25       Impact factor: 47.728

8.  Effect of cell surface antigen density on immunological enhancement.

Authors:  W D Linscott
Journal:  Nature       Date:  1970-11-28       Impact factor: 49.962

9.  Tissue injury in lymphocytic choriomeningitis viral infection: virus-induced immunologically specific release of a cytotoxic factor from immune lymphoid cells.

Authors:  M B Oldstone; F J Dixon
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

10.  The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency.

Authors:  J A Manni; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1969-11-01       Impact factor: 14.307

View more
  32 in total

1.  Ultrastructural and serological studies on the resistance of activated B cells to the cytotoxic effects of anti-immunoglobulin serum. Patch and cap formation of surface immunoglobulin on mitotic B lymphocytes.

Authors:  R S Kerbel; M S Birbeck; D Robertson; P Cartwright
Journal:  Clin Exp Immunol       Date:  1975-04       Impact factor: 4.330

2.  Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent.

Authors:  P J Leibson; H Schreiber; M R Loken; S Panem; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

Review 3.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

4.  Sensitivity of phases of the mitotic cycle of tumor cells to the action of immune lymphocytes.

Authors:  N V Leneva; G Y Svet-Moldavskii
Journal:  Bull Exp Biol Med       Date:  1974-06       Impact factor: 0.804

5.  Lymphocyte activation. I. Expression of theta, H-2 and immunoglobulin determinants on lymphocytes stimulated by phytohaemagglutinin, pokeweed mitogen, concanavalin A or histocompatibility antigen.

Authors:  G Jones
Journal:  Clin Exp Immunol       Date:  1972-11       Impact factor: 4.330

6.  Proliferative parameters of mammalian cell systms and their rôle in tumor growth and carcinogenesis.

Authors:  M F Rajewsky
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1972

7.  Dissociation of H-2 recognition by antibody and cytotoxic T cells of a cloned murine leukemia cell line.

Authors:  J L Portis; F J McAtee
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

8.  Karyotypic, virologic, and immunologic analyses of two continuous lymphocyte lines established from New Zealand black mice: possible relationship of chromosomal mosaicism to autoimmunity.

Authors:  R A Lerner; F Jensen; S J Kennel; F J Dixon; G Des Roches; U Francke
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

9.  Cell mitotic cycle synthesis of NIL hamster glycolipids including the Forssman antigen.

Authors:  B A Wolf; P W Robbins
Journal:  J Cell Biol       Date:  1974-06       Impact factor: 10.539

10.  Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.

Authors:  P L Nara; W G Robey; M A Gonda; S G Carter; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.